WT
AKRO

Whittier Trust’s Akero Therapeutics AKRO Stock Holding History

Whittier Trust’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-157
Closed -$4.37K – 1493
2024
Q4 		$4.37K Hold
157
– – ﹤0.01% 1381
2024
Q3 		$4.5K Hold
157
– – ﹤0.01% 1387
2024
Q2 		$3.68K Buy
+157
New +$3.36K ﹤0.01% 1374

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Whittier Trust's AKRO Position: Q1 2025 in Review

Whittier Trust sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 157 shares — an estimated $4.37K sold.

Whittier Trust first reported a position in AKRO in Q2 2024 and held it in 3 quarters. The position peaked at $4.5K in Q3 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Whittier Trust reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Whittier Trust sold 157 Akero Therapeutics shares in Q1 2025, an estimated $4.37K.
  • Whittier Trust first reported a position in Akero Therapeutics in Q2 2024 and held it in 3 quarters.
  • Whittier Trust's Akero Therapeutics position peaked at $4.5K in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Whittier Trust's 13F filing for Q1 2025, filed 2 May 2025.